Century Therapeutics, Inc. (IPSC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 40M 80M 120M Q1 '22: 1.1M Q2 '22: 1.4M Q3 '22: 2.2M Q4 '22: 521K Q1 '23: 1.7M Q2 '23: 99K Q3 '23: 148K Q4 '23: 268K Q1 '24: 855K Q2 '24: 771K Q3 '24: 791K Q4 '24: 4.2M Q1 '25: 109.2M Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q2 '22 Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-60M -30M 0 30M 60M 90M Q1 '20: -10M Q2 '20: -15.5M Q3 '20: -13.1M Q4 '20: -15.3M Q1 '21: -18.1M Q2 '21: -23M Q3 '21: -25.8M Q4 '21: -28M Q1 '22: -37.4M Q2 '22: -31.4M Q3 '22: -31.7M Q4 '22: -33.3M Q1 '23: -32.1M Q2 '23: -35.1M Q3 '23: -35.6M Q4 '23: -43.8M Q1 '24: -31.3M Q2 '24: -34.8M Q3 '24: -34.8M Q4 '24: -37.3M Q1 '25: 74.2M Q2 '25: -34.7M Q3 '25: -36.1M Q4 '25: -20.7M Q1 '26: -23.7M Q2 '26: -36.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income Quarterly

-60M -30M 0 30M 60M 90M Q1 '20: -9.7M Q2 '20: -15.3M Q3 '20: -13.1M Q4 '20: -15.5M Q1 '21: -18.3M Q2 '21: -23.3M Q3 '21: -26M Q4 '21: -28.2M Q1 '22: -37.5M Q2 '22: -31M Q3 '22: -30.7M Q4 '22: -31.7M Q1 '23: -31.3M Q2 '23: -33.3M Q3 '23: -32.7M Q4 '23: -39.4M Q1 '24: -28.1M Q2 '24: -31.2M Q3 '24: -31.2M Q4 '24: -36.1M Q1 '25: 76.6M Q2 '25: -32.5M Q3 '25: -34.4M Q4 '25: -19.2M Q1 '26: -21.6M Q2 '26: -34.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-60M -30M 0 30M 60M 90M Q3 '20: -9.2M Q4 '20: -13.2M Q1 '21: -22.2M Q2 '21: -18.5M Q3 '21: -24M Q4 '21: -24.4M Q1 '22: 86.8M Q2 '22: -25.6M Q3 '22: -24.2M Q4 '22: -22.9M Q1 '23: -29.2M Q2 '23: -19.2M Q3 '23: -13.6M Q4 '23: -26.2M Q1 '24: -30.2M Q2 '24: -27.3M Q3 '24: -28.3M Q4 '24: -24.2M Q1 '25: -34.6M Q2 '25: -27.6M Q3 '25: -25.6M Q4 '25: -16.1M Q1 '26: -25.3M Q2 '26: -19.8M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-60M -30M 0 30M 60M 90M Q3 '20: -13.7M Q4 '20: -15.1M Q1 '21: -24.1M Q2 '21: -29.1M Q3 '21: -39.7M Q4 '21: -41.1M Q1 '22: 82.7M Q2 '22: -36M Q3 '22: -34M Q4 '22: -29.2M Q1 '23: -34.2M Q2 '23: -23.8M Q3 '23: -16.9M Q4 '23: -27.2M Q1 '24: -30.8M Q2 '24: -27.6M Q1 '25: -35.1M Q2 '25: -27.9M Q3 '25: -25.8M Q1 '26: -25.8M Q2 '26: -20.5M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q2 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q2 '20: 7.5M Q3 '20: 7.5M Q1 '21: 7.7M Q2 '21: 12M Q3 '21: 54.5M Q1 '22: 57.1M Q2 '22: 57.7M Q3 '22: 58M Q1 '23: 58.6M Q2 '23: 59.3M Q3 '23: 59.4M Q1 '24: 62.3M Q2 '24: 82.1M Q3 '24: 84.7M Q1 '25: 86.1M Q2 '25: 86.2M Q3 '25: 86.5M Q1 '26: 193.5M Q2 '26: 205.8M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-9.00 -6.00 -3.00 0.00 3.00 6.00 9.00 Q4 '20: -7.16 Q1 '21: -8.27 Q2 '21: -8.15 Q3 '21: -6.88 Q4 '21: -2.96 Q1 '22: -1.23 Q2 '22: 0.16 Q3 '22: 0.11 Q4 '22: -2.97 Q1 '23: -2.84 Q2 '23: -2.86 Q3 '23: -2.88 Q4 '23: -2.29 Q1 '24: -2.21 Q2 '24: -2.03 Q3 '24: -1.85 Q4 '24: -1.63 Q1 '25: -0.29 Q2 '25: -0.29 Q3 '25: -0.32 Q4 '25: -0.14 Q1 '26: -1.14 Q2 '26: -0.93 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.